Molecular Characteristics and Prognostic Role of EPHA2 in Human Tumors Via Pan-cancer Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Nov 29

PMID 39612413

Authors

Guoqiang Wang

Hui Xiao

Zhipan Liang

Yuxin Feng

Liyu Wang

Ying Feng

Fen Guo

Luyao Zhang

Affiliations

Soon will be listed here.

Abstract

The tyrosine kinase ephrin type-A receptor 2 (EPHA2) was remarkably elevated expressed in various tumors and plays a crucial role in cancer tumorigenesis and progression, while pan-cancer analyses are currently lacking. This study was designed to analyze the expression status and prognostic significance of EPHA2 in pan-cancer. By mining The Cancer Genome Atlas data, we performed a comprehensive and systematic characterization of EPHA2 across >10,000 samples of 33 types of cancer. EPHA2 expressions were substantially different in most of the normal control and tumor tissues, and it was considerably associated with the prognosis of tumor patients. EPHA2 gene modifications in malignant tumors were mainly missense mutations. There was a significant correlation between EPHA2 expression and cancer-associated fibroblasts in most The Cancer Genome Atlas cancers. Furthermore, functional enrichment analysis showed that the biological role of EPHA2 in tumors was mainly involved in some noticeably pro-oncogenic pathways, such as the Ras signaling pathway, PI3K-Akt signaling pathway, ErbB signaling pathway, MAPK signaling pathway, etc. This study provided the first pan-cancer analyses of EPHA2 in various tumors, and EPHA2 was potentially involved in many cancer types and can be developed as candidates for cancer diagnosis, prognosis, and therapeutic biomarkers. In addition, EPHA2 seemed to be a key modulator of the tumor immune microenvironment and might be a potential biomarker in predicting the immunotherapeutic efficacy for cancer patients.

References

Baharuddin W, Yusoff A, Abdullah J, Osman Z, Ahmad F . Roles of EphA2 Receptor in Angiogenesis Signaling Pathway of Glioblastoma Multiforme. Malays J Med Sci. 2019; 25(6):22-27. PMC: 6422564. DOI: 10.21315/mjms2018.25.6.3. View

Ruiz J, Robertson E . The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech Dev. 1994; 46(2):87-100. DOI: 10.1016/0925-4773(94)90078-7. View

Wei Y, Jiao Z, Sun T, Lai Z, Wang X . Molecular Mechanisms Behind Vascular Mimicry as the Target for Improved Breast Cancer Management. Int J Womens Health. 2023; 15:1027-1038. PMC: 10350405. DOI: 10.2147/IJWH.S406327. View

Zhou Y, Sakurai H . Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression. Biol Pharm Bull. 2017; 40(10):1616-1624. DOI: 10.1248/bpb.b17-00446. View

Xiao T, Xiao Y, Wang W, Tang Y, Xiao Z, Su M . Targeting EphA2 in cancer. J Hematol Oncol. 2020; 13(1):114. PMC: 7433191. DOI: 10.1186/s13045-020-00944-9. View

Zhao P, Jiang D, Huang Y, Chen C . EphA2: A promising therapeutic target in breast cancer. J Genet Genomics. 2021; 48(4):261-267. DOI: 10.1016/j.jgg.2021.02.011. View

Lisabeth E, Falivelli G, Pasquale E . Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 2013; 5(9). PMC: 3753714. DOI: 10.1101/cshperspect.a009159. View

Brantley-Sieders D, Zhuang G, Hicks D, Fang W, Hwang Y, Cates J . The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2007; 118(1):64-78. PMC: 2129239. DOI: 10.1172/JCI33154. View

Wilson K, Shiuan E, Brantley-Sieders D . Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021; 40(14):2483-2495. PMC: 8035212. DOI: 10.1038/s41388-021-01714-8. View

10.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

11.

Tandon M, Vemula S, Mittal S . Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets. 2010; 15(1):31-51. PMC: 3016619. DOI: 10.1517/14728222.2011.538682. View

12.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

13.

Ireton R, Chen J . EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005; 5(3):149-57. DOI: 10.2174/1568009053765780. View

14.

Wang H, Hou W, Perera A, Bettler C, Beach J, Ding X . Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep. 2021; 34(8):108765. PMC: 7954228. DOI: 10.1016/j.celrep.2021.108765. View

15.

Mo J, Zhao X, Dong X, Liu T, Zhao N, Zhang D . Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level. Cell Oncol (Dordr). 2020; 43(4):655-667. DOI: 10.1007/s13402-020-00511-x. View

16.

Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H . EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer. 2002; 103(5):657-63. DOI: 10.1002/ijc.10860. View

17.

De Robertis M, Loiacono L, Fusilli C, Poeta M, Mazza T, Sanchez M . Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clin Cancer Res. 2016; 23(1):159-170. PMC: 5822042. DOI: 10.1158/1078-0432.CCR-16-0709. View

18.

Liu X, He H, Zhang F, Hu X, Bi F, Li K . m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022; 13(5):483. PMC: 9122982. DOI: 10.1038/s41419-022-04950-2. View

19.

Dunne P, Dasgupta S, Blayney J, McArt D, Redmond K, Weir J . EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clin Cancer Res. 2015; 22(1):230-242. PMC: 4694030. DOI: 10.1158/1078-0432.CCR-15-0603. View

20.

Kurose H, Ueda K, Kondo R, Ogasawara S, Kusano H, Sanada S . Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer. Anticancer Res. 2019; 39(11):6249-6257. DOI: 10.21873/anticanres.13834. View